For several decades the standard of care in patients with poor-risk non-seminomatous germ-cell tumours (NSGCT) has been 4 cycles of bleomycin, etoposide and cisplatin (BEP). However, there are data to support that in patients with an unfavourable decline in tumour markers after a first cycle of BEP, a high-dose chemotherapy regimen should become the standard of care. Dr. Fizazi also insisted on the importance of centralisation of care and provided some new insights for the treatment of patients with germ-cell tumours (GCT) following a relapse.